Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of orienX010 in stage IV melanoma with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback